NHWK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (5 Feb 2024 @ 15:58):

Stats
Today's Volume	161 222
Average Volume	163 739
Market Cap	10.78M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.202
ATR14	$0.0430 (13.71%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-07	Wolf Jeffrey Alan	Buy	2 843 137	Stock Option (right to buy)
2022-12-07	Smith Edward B Iii	Buy	101 960	Stock Option (right to buy)
2022-12-07	Prendergast John K A	Buy	203 921	Stock Option (right to buy)
2022-12-07	Ostrander William L.	Buy	490 196	Stock Option (right to buy)
2022-12-07	Monahan John J	Buy	101 960	Stock Option (right to buy)

INSIDER POWER
100.00
Last 95 transactions
Buy: 24 129 486 \| Sell: 659 541

Volume Correlation

Long: -0.20 (neutral)

Short: -0.48 (neutral)

Signal:(40.526) Neutral

NightHawk Biosciences, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NightHawk Biosciences, Correlation - Currency/Commodity

-0.24
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.17
( neutral )

0.12
( neutral )

-0.10
( neutral )

NightHawk Biosciences, Financials

Annual	2022
Revenue:	$5.98M
Gross Profit:	$-420 025 (-7.02 %)
EPS:	$-1.710

FY	2022
Revenue:	$5.98M
Gross Profit:	$-420 025 (-7.02 %)
EPS:	$-1.710

FY	2021
Revenue:	$2.11M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.410

FY	2020
Revenue:	$2.95M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.630

Financial Reports:

No articles found.

NightHawk Biosciences,

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.